Fibrin Monomer (FM)
in Obstetrics venous thromboembolism (VTE)

Fibrin Monomer: a promising maker in early diagnosis of thrombosis.

According to Ulrich-Peter Rohr et al. (1), approximately 75% of clinical decisions are based on medical diagnostic tests. Through health economic studies, early diagnostics is proven to save treatment costs, reduce hospitalization rates, and reduce pressure on hospitals and healthcare professionals.

Fibrin Monomer (FM) is considered a promising marker in early diagnosis of thrombosis. FM (SFM) is mentioned in the ISTH recommendations on DIC diagnostic algorithms. FM has been also being applied in Vietnam recently relating to sepsis and shock sepsis, especially in the application of screening and diagnosis of venous thromboembolism (VTE) in Obstetrics.

VTE is a significant cause of maternal morbidity and mortality worldwide. In the United States, thromboembolic disorders – deep thrombophlebitis (DVT) or pulmonary embolism (PE) – are the leading cause of maternal morbidity and mortality in pregnant women. The risk of VTE in this group of subjects increases 5-fold during pregnancy and 60-fold in the first three months after giving birth compared to non-pregnant women (4). FM helps clinicians effectively control the risk and condition of thrombosis, ensuring safety for mothers and fetuses throughout pregnancy and giving birth.

The FM test has shown superiority over D-Dimer in identifying active thrombosis in women with normal pregnancies. Therefore, FM helps optimize the appointment of anticoagulant treatment, including starting and ending times.

Most pregnant women have D-Dimer levels increased above normal levels due to physiology or pathology. Meanwhile, FM has a relatively stable concentration in normal pregnancy. FM is created before a blood clot is formed (Fibrin), reflecting increased thrombin formation. Increased FM is an early predictor of thrombosis.

Refer to the concluding study on the application value of FM, which is more specific in diagnosing VTE in Obstetrics than D-Dimer: Fibrin monomer complex as a potential thrombosis marker related to venous thromboembolism risk in pregnant women


  1. Early diagnostics: Shaping healthcare and society through new technologies. (2021, September 21). European Institute of Innovation & Technology (EIT).
  2. Raia-Barjat, T. et al. (2022). Venous Thromboembolism Risk Score and Pregnancy. Frontiers in Cardiovascular Medicine, 9.
  3. Jean‐Christophe Gris et al. (2018). Clinical value of automated fibrin generation markers in patients with septic shock: a SepsiCoag ancillary study. British Journal of Haematology, 183(4), 636–647.
  4. Levi, M. et al. (2009). Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. British Journal of Haematology, 145(1), 24–33.
  5. Refaai, M. et al. (2018). The Clinical Significance of Fibrin Monomers. Thrombosis and Haemostasis, 118(11), 1856–1866.
  6. Toh, J. M. H. et al. (2013). The clinical utility of fibrin-related biomarkers in sepsis. Blood Coagulation & Fibrinolysis, 24(8), 839–843.